FY2019 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Reduced by Analyst

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Analysts at Cantor Fitzgerald reduced their FY2019 earnings estimates for shares of Vanda Pharmaceuticals in a research report issued to clients and investors on Thursday, May 2nd. Cantor Fitzgerald analyst C. Duncan now forecasts that the biopharmaceutical company will post earnings of $0.25 per share for the year, down from their previous estimate of $0.62. Cantor Fitzgerald currently has a “Reduce” rating and a $26.00 target price on the stock.

A number of other analysts have also issued reports on VNDA. ValuEngine lowered Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 18th. Zacks Investment Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a report on Thursday, April 18th. BidaskClub lowered Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, April 11th. Oppenheimer set a $18.00 price target on Vanda Pharmaceuticals and gave the company a “hold” rating in a report on Sunday. Finally, Citigroup lowered Vanda Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Thursday, May 2nd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. Vanda Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $33.63.

Shares of NASDAQ VNDA opened at $16.50 on Monday. The company has a market capitalization of $841.60 million, a P/E ratio of 34.38, a PEG ratio of 4.82 and a beta of 0.44. Vanda Pharmaceuticals has a 52-week low of $13.66 and a 52-week high of $33.44.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.08). The firm had revenue of $47.71 million during the quarter, compared to analysts’ expectations of $51.74 million. Vanda Pharmaceuticals had a net margin of 10.92% and a return on equity of 8.07%. The firm’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.14 EPS.

In other Vanda Pharmaceuticals news, CFO James Patrick Kelly sold 8,751 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $19.88, for a total transaction of $173,969.88. Following the completion of the sale, the chief financial officer now owns 218,497 shares in the company, valued at $4,343,720.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Mihael Hristos Polymeropoulos sold 38,166 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $19.41, for a total value of $740,802.06. Following the sale, the chief executive officer now owns 1,217,136 shares of the company’s stock, valued at approximately $23,624,609.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,274 shares of company stock valued at $1,164,127. 7.80% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc increased its position in shares of Vanda Pharmaceuticals by 18.8% during the third quarter. Vanguard Group Inc now owns 3,969,954 shares of the biopharmaceutical company’s stock worth $91,111,000 after purchasing an additional 629,086 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Vanda Pharmaceuticals by 18.8% during the third quarter. Vanguard Group Inc. now owns 3,969,954 shares of the biopharmaceutical company’s stock worth $91,111,000 after purchasing an additional 629,086 shares in the last quarter. First Manhattan Co. increased its position in shares of Vanda Pharmaceuticals by 13.8% during the fourth quarter. First Manhattan Co. now owns 939,374 shares of the biopharmaceutical company’s stock worth $24,545,000 after purchasing an additional 113,999 shares in the last quarter. TIAA CREF Investment Management LLC increased its position in shares of Vanda Pharmaceuticals by 6.1% during the third quarter. TIAA CREF Investment Management LLC now owns 727,023 shares of the biopharmaceutical company’s stock worth $16,685,000 after purchasing an additional 41,687 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Vanda Pharmaceuticals by 7.1% during the fourth quarter. Bank of New York Mellon Corp now owns 632,889 shares of the biopharmaceutical company’s stock worth $16,537,000 after purchasing an additional 42,218 shares in the last quarter. Institutional investors own 99.45% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Further Reading: Net Income

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.